Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Recent News
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


The JALMA Institute Signs Purchase Agreement for Nutra Pharma's NTM Test Kits
May 03, 2006

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma, has received orders from Dr. V. M. Katoch for the NTM Diagnostic Test Kits designed for the rapid identification of Nontuberculous Mycobacterium (NTM). Dr. Katoch is the director of the Central JALMA Institute of Leprosy and other Mycobacterial Diseases. The Institute was founded in 1976 and is currently a leading institute for leprosy and mycobacterial research.

“We are very excited about working with Dr. Katoch and his organization,” commented Neil Roth, President of Designer Diagnostics. “We believe that the Designer Diagnostics NTM Test Kits will add tremendous value to the research that is being conducted in India. Our team will continue to work closely with Dr. Katoch to ensure the future success and performance of the test kit technology,” he added.

“We believe that the NTM Test Kits address a huge market for Designer Diagnostics,” explained Rik J Deitsch, Nutra Pharma’s CEO. “NTMs and Tuberculosis (TB) account for the majority of deaths in HIV/AIDS patients. The occurrence of NTMs is dramatically increasing as the number of HIV/AIDS and other immuno-suppressed patients increase. There are currently more than 40 million people around the world who should be tested for these diseases,” he concluded.

The first shipments of the NTM Test Kits have been delivered to the Institute. These sales represent the first revenue generated by Designer Diagnostics and Nutra Pharma Corporation.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The sale of NTM Test Kits to the JALMA Institute should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
January 18, 2018
Nutra Pharma Partners with EuroAmerican IP to Distribute Nyloxin for Sale to Government Agencies

December 29, 2017
Nutra Pharma Letter to Shareholders

August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics